Related Experiment Video
Updated: May 3, 2026
An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
Published on: January 9, 2020
Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy
Xiaohong Bi1, Brent Rexer2, Carlos L Arteaga2
1Vanderbilt University, Department of Biomedical Engineering, VU Station B #351631, 2301 Vanderbilt Place, Nashville, Tennessee 37235bUniversity of Texas Health Science Center at Houston, Department of Nanomedicine and Biomedical Engineering, CABIR 3SCR.46.
Abstract:
The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance. This study applied Raman spectroscopy to differentially identify the amplification status of HER2 in cells and to characterize the biochemical composition of lapatinib resistant and sensitive HER2+ breast cancer cells in response to the drug. Raman spectra from BT474 (HER2+ breast cancer cell), MCF-10A (HER2- control), and HER2+ MCF-10A (HER2+ control) were analyzed using lasso and elastic-net regularized generalized linear models (glmnet) for multivariate statistical analysis and were discriminated to groups of different HER2 expression status with an overall 99% sensitivity and specificity. Enhanced lipid content and decreased proteome were observed in HER2+ cells. With lapatinib treatment, lapatinib-resistant breast cancer cells demonstrated sustained lipogenesis compared with the sensitive cells.
Insights
Raman spectroscopy accurately identified human epidermal growth factor receptor 2 (HER2) status in breast cancer cells. Resistant cells showed increased lipids and sustained lipogenesis after lapatinib treatment.
Area of Science:
- Biochemistry
- Cancer Biology
- Spectroscopy
Background:
- Overexpression of human epidermal growth factor receptor 2 (HER2) is linked to poor breast cancer prognosis and recurrence.
- Targeted therapies like lapatinib for HER2+ breast cancer can be limited by acquired drug resistance.
Purpose of the Study:
- To utilize Raman spectroscopy for differentiating HER2 amplification status in breast cancer cells.
- To characterize the biochemical differences between lapatinib-sensitive and resistant HER2+ breast cancer cells.
Main Methods:
- Raman spectroscopy was employed to analyze breast cancer cell lines (BT474, MCF-10A, HER2+ MCF-10A).
- Multivariate statistical analysis using glmnet models differentiated cells based on HER2 expression.
- Biochemical composition changes in response to lapatinib were investigated.
Main Results:
- Raman spectroscopy achieved 99% sensitivity and specificity in discriminating HER2 expression levels.
- HER2+ cells exhibited higher lipid content and reduced proteome compared to HER2- cells.
- Lapatinib-resistant cells displayed sustained lipogenesis, unlike sensitive cells.
Conclusions:
- Raman spectroscopy is a viable method for assessing HER2 status in breast cancer.
- Biochemical alterations, particularly enhanced lipogenesis, characterize lapatinib resistance in HER2+ breast cancer.
Related Concept Videos
01:20Raman Spectroscopy: Overview
However, a small fraction of the scattered light exhibits a frequency shift due to the exchange of energy between the incident photons and...
01:26Raman Spectroscopy Instrumentation: Overview
The monochromatic laser source, typically using visible or near-infrared radiation, generates a highly focused beam of light. This light interacts with the molecules of the sample, scattering some of the light. Liquid and gaseous samples are usually tested in ordinary glass capillaries, while solids can be analyzed as powders packed in capillaries or as potassium...